Robotic Lumbar Fusion Cut Hospital Opioid Use 16 Percent, HSS Finds

Patients who had minimally invasive lumbar fusion surgery with robotic arm guidance used 16 percent less opioid medication during their hospital stay than patients whose operations were guided by conventional navigation, and they were significantly less likely to need intravenous patient-controlled analgesia, according to research from Hospital for Special Surgery presented Oct. 15 at the North American Spine Society annual meeting in San Antonio. The complication rate and the length of stay were statistically indistinguishable between the two groups, the researchers reported.

How the comparison was built

The study, titled "Comparison of Opioid Utilization After Robotic Arm-Assisted and Navigation-Guided Minimally Invasive Transforaminal Lumbar Interbody Fusion," drew on a prospectively maintained spine surgery registry at HSS and covered 804 patients who had one- or two-level lumbar fusion between 2017 and 2025. Of those, 203 were treated with navigation-guidance and 601 with robotic arm assistance. The analysis adjusted for differences in patient characteristics and for the surgeons who performed the operations, which matters in a registry study where a single high-volume surgeon could otherwise drive the result.

Transforaminal lumbar interbody fusion is a common operation for degenerative spine conditions. Minimally invasive versions of it already rely on imaging and navigation systems to place spinal implants through small incisions, and robotic platforms add a further layer of stability and precision to that placement. Until now, most comparative research on the robots has measured how accurately they put screws where the surgeon intended, and how much time the procedure takes. Whether the technology changes what happens to a patient afterward — specifically how much opioid painkiller they need — has been studied much less.

The reductions, itemized

The differences HSS reported were concentrated in the immediate postoperative window. Total in-hospital opioid consumption fell 16 percent in the robotic-assisted group. In the first 24 hours after surgery — the period when pain is typically at its worst and when prescribing decisions set the trajectory for a patient's discharge — opioid use dropped 21 percent. The likelihood of needing intravenous patient-controlled analgesia, a pump the patient activates and generally a step up in intensity from oral medication, fell 57 percent.

Zeros in the other direction are as important as those numbers. There were no significant differences in complications or in hospital length of stay, meaning the opioid reduction did not come from shorter admissions or from a group that was healthier to begin with.

"Reducing patients' exposure to opioid medications after surgery remains an important goal in spine care," said Sheeraz A. Qureshi, MD, MBA, co-chief of HSS Spine and a co-author of the study. "While robotic technology is often recognized for improving surgical precision, these results suggest its benefits may extend beyond the operating room."

Where the finding lands in opioid-sparing care

The result arrives as spine surgeons look for ways to cut opioid exposure without leaving postoperative pain untreated. Surgical prescribing is a persistent pipeline into dependence: a patient can leave a hospital with a legitimate prescription, take the medication as directed, and still end up with a supply that has to be managed, stored or disposed of. Public health agencies have for years pointed to prescription painkillers as among the most frequently misused classes of medication, and medication take-back programs exist in part because of the leftovers that accumulate after routine operations. Efforts to narrow that pipeline have run along two tracks — changing what is prescribed, and changing what is done in the operating room, which is where this study sits. Non-opioid drug development has moved in parallel; the Food and Drug Administration approved a first-in-class non-opioid pain medication in 2026, a milestone this blog covered in August.

"We observed a consistent reduction in opioid utilization among patients who underwent robotic-assisted surgery, including lower overall opioid consumption and substantially less need for intravenous patient-controlled analgesia," said Kyle W. Morse, MD, a spine surgeon at HSS and a co-author. "Importantly, these reductions occurred while maintaining similar safety outcomes. These findings suggest robotic guidance may offer meaningful benefits for patients recovering from lumbar fusion surgery and could play an important role in future opioid-sparing perioperative care pathways."

What a conference presentation does not settle

The findings were presented at a professional meeting and distributed by the hospital as a news release, not published as a peer-reviewed paper, so the underlying data have not yet been through journal review. Several questions go unanswered at this stage.

The registry captures care at a single specialty orthopedic institution, which limits how far the results can be projected onto community hospitals with different case mixes, different opioid protocols and different robot experience. The study also measures opioid use only during hospitalization; whether the reduction persists after discharge, when most of a surgical prescription is actually consumed, is not part of the result. And it reports no patient-reported pain scores, so it does not establish whether patients in the robotic group were in more pain despite taking less medication — a distinction that matters to how the finding should be used.

What it does support is a narrower claim: in one large academic spine practice, the choice of guidance technology was associated with how much opioid medication patients needed while they were in the hospital, and with how often they needed the strongest form of it. For patients already managing an opioid use disorder, surgery raises separate questions about tolerance, withdrawal prevention and coordination with a prescriber, which the study does not address.